Guilin Sanjin (002275.SZ) recently stated during a reception for institutional investors that the company mainly produces dual-use drugs, with varying proportions for each type. Overall, OTC drugs are the main focus, while prescription drugs are a secondary focus, accounting for approximately 80% and 20%, respectively. For the Watermelon Frost series, the proportion of OTC drugs is always higher than prescription drugs, approximately 80% to 20%, while the hospital usage of Sanjin Tablets is slightly higher than Watermelon Frost.